Myeloproliferative neoplasms (MPNs) are a group of blood cancers that cause excess blood cell production in the bone marrow and often in the peripheral blood, and are characterized by clonal genetic changes. MPNs include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic neutrophilic leukemia (CNL), and chronic eosinophilic leukemia (CEL). CML, which is discussed separately, is defined by the presence of the BCR-ABL1 fusion gene; the other MPN types are BCR-ABL1 negative. The majority of patients with PV, ET, and PMF have a mutation in the JAK2, CALR, or MPL gene, which carries implications for classification, diagnosis, and prognosis; however, other clonal markers may also be diagnostic for MPN.
Laboratory testing for the evaluation of MPN includes an initial workup of blood counts (CBC). Peripheral blood smear microscopy, bone marrow histology, cytogenetics, and genetic profiling complete the diagnostic testing. A diagnosis is made when results of these studies meet the specific diagnostic criteria for a particular MPN subtype. Distinguishing MPN types and grades is essential because treatments vary and long-term clinical outcomes differ significantly among the subtypes.
Quick Answers for Clinicians
Myeloproliferative neoplasms (MPNs) are characterized by an overproduction of red blood cells, platelets, or certain white blood cells; myelodysplastic syndromes (MDSs) are characterized by overproduction of defective, dysplastic myeloid cells, which results in peripheral blood cytopenias. The diseases classified as MDS/MPN exhibit both dysplastic and proliferative features. MDS/MPN disorders include chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML), MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), and unclassifiable MDS/MPN.
The diagnosis of myeloproliferative neoplasms (MPNs) requires a combination of CBC and peripheral smear examination, bone marrow histology, chromosome analysis, and molecular testing. The combination of these studies allows clinicians to determine whether results meet corresponding diagnostic criteria. Subclassification often requires a bone marrow biopsy with ancillary cytogenetic and molecular testing.
Next generation sequencing (NGS) panels that include JAK2, MPL, and CALR genes may be used in place of individual gene tests in the initial diagnostic workup of myeloproliferative neoplasms (MPNs); NGS may also be especially useful to establish clonality in the diagnosis of triple-negative MPNs, in which JAK2, MPL, and CALR gene mutations are not present. Furthermore, NGS can identify multiple spliceosome genes and can also identify additional prognostically relevant mutations. NGS testing is recommended in select patients to evaluate for higher-risk mutations that are associated with disease progression.
Coagulation testing to evaluate for acquired von Willebrand disease (VWD) and/or other coagulopathies is recommended in patients with an elevated platelet count and/or unexplained bleeding, and in those who are undergoing high-risk surgical procedures. If hematopoietic cell transplantation is being considered, human leukocyte antigen (HLA) type testing performed on a blood sample is necessary for donor matching.
Indications for Testing
Along with medical history, symptom assessment, and physical examination, the following nonspecific laboratory tests are recommended as part of the initial evaluation in the diagnostic workup of MPNs: CBC, peripheral blood smear, comprehensive metabolic panel (including lactate dehydrogenase [LDH], liver function, and serum uric acid tests), serum erythropoietin (EPO), and serum iron level measurements. If the results of these tests suggest the possibility of MPN, molecular testing, chromosome analysis, and bone marrow staining are indicated.
The following are the major MPN subtypes, not including CML.
|PV||High number of RBCs (high hemoglobin, red cell mass)
Risk of post-PV MF with poor outcome
|ET||High number of platelets and increased numbers of large, atypical megakaryocytes in the bone marrow
Fibrosis is rare; can indicate initial misdiagnosis of early-phase PMF
|PMF||De novo MF (rather than from the transformation of PV to MF)
Leukoerythroblastic blood smear with dacryocytes if marrow is fibrotic
Bone marrow fibrosis might be absent or minimal in early-stage/prefibrotic PMF
Reticulin or collagen fibrosis is considerable in overt PMF
|CNL||Sustained mature neutrophilia in peripheral blood, hepatosplenomegaly, and hypercellularity in bone marrow due to neutrophilic granulocyte proliferation
CSF3R mutations are common but not specific
|CEL, NOS||Eosinophilia is the dominant hematologic abnormality caused by autonomous, clonal proliferation of eosinophil precursors
Evidence of clonality; abnormal bone marrow morphology common
|MPN-U||Designated for cases with features of an MPN but which do not meet diagnostic criteria, whether because distinguishing features are not fully developed or because the subtype is obscured by an advanced stage or another condition|
|MF, myelofibrosis; MPN-U, MPN, unclassifiable; NCCN, National Comprehensive Cancer Network; NOS, not otherwise specified; RBC, red blood cell; WHO, World Health Organization|
The diagnosis of MPN should be based on the 2017 WHO diagnostic criteria. Criteria include specific findings from the CBC, blood smear, and bone marrow analysis, correlated with clinical history as well as the presence of certain molecular markers and the exclusion of other disorders.
Testing for BCR-ABL1 Mutation
Testing of peripheral blood or bone marrow by fluorescence in situ hybridization (FISH) is best for initial screening because it will detect rare breakpoints that may not always be detected by molecular methods. Multiplex reverse transcriptase polymerase chain reaction (RT-PCR) can also be used to confirm and monitor the BCR-ABL1 fusion gene, the presence of which is diagnostic for CML in the appropriate context; the absence of BCR-ABL1 by FISH essentially excludes CML, and testing for other MPN mutations should be performed. For testing specific to CML, see the Chronic Myelogenous Leukemia topic.
Testing for Other Mutations
Molecular testing is used to assess clonality and to detect MPN-specific mutations. Molecular testing of blood should be performed first for the JAK2 V617F mutation in all patients because it is the most common mutation and occurs in most patients (>95%) with PV. If the JAK2 V617F mutation is not detected, testing for CALR and then MPL mutations should follow for patients with ET or PMF. If PV is still suspected in those with negative JAK2 V617F mutation results, testing should be performed for JAK2 exon 12 mutations. In those with ET or PMF but without JAK2, MPL, or CALR mutations (triple-negative MPNs), testing for mutations in ASXL1, CBL, CSF3R, DNM3TA, EZH2, IDH1, IDH2, LINK/SH2B3, SF3B1, SRSF2, TET2, TP53, and U2AF1 genes should then be considered. A comprehensive next generation sequencing (NGS) myeloid panel can be useful for this testing.
Patients with molecular evidence of PDGFRA, PDGFRB, FGRF1, or PCM1-JAK2 rearrangements are considered to have myeloid/lymphoid neoplasms of a different classification from MPN.
Testing using a multigene NGS panel that includes JAK2, CALR, and MPL may be used instead of single-gene tests. NGS provides the benefit of identifying additional mutations that may have prognostic importance.
Cytogenetic analysis is important in distinguishing MPN subtypes. The chromosome analysis also serves to provide evidence of clonality and clonal evolution over time, and to assess the success of treatment. Chromosomal evaluation (eg, karyotype) is performed with or without FISH and should be done with bone marrow biopsy when possible. The Philadelphia chromosome, which results from a reciprocal translocation of chromosomes 9 and 22 and affects the BCR-ABL1 fusion gene, is the hallmark of CML. Although specific chromosomal abnormalities have not been identified for MPNs other than CML, abnormalities range from <5-30% and are varied. Complex karyotypes are defined as three or more unrelated chromosomal abnormalities, or one or two abnormalities that include trisomy 8, 7/7q-, i(17q), 5/5q-, 12p-, inv(3), or 11q23 rearrangement. These abnormalities have prognostic significance and may predict the transformation of MPN to acute myeloid leukemia (AML).
Bone Marrow Staining
Bone marrow evaluation is used to confirm a diagnosis of MPN and to assess the blast percentage and any evidence of fibrosis, which help to determine the prognosis. Trichrome and reticulin staining of bone marrow aspirate or biopsy is necessary to accurately assess the degree of fibrosis. Bone marrow histology should be assessed to rule out disease progression to MF before starting cytoreductive therapy.
The overall survival of patients with MPNs is variable depending on the subtype. Several scoring systems and prognostic models have been developed for the risk stratification of patients with MPNs. See the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms for recommendations on risk stratification.
Monitoring of Treatment Effects
Ruxolitinib has been associated with increased levels of total cholesterol, low-density lipoprotein cholesterol, and triglycerides; thus, assessment of lipid profiles should be performed 8-12 weeks following initiation of ruxolitinib. Patients with high lipid levels should be monitored and treated according to clinical guidelines for hyperlipidemia. See Atherosclerotic Cardiovascular Disease Risk Markers for information on screening and testing for dyslipidemia.
- Renal impairment
- Hepatic impairment
- Bacterial, mycobacterial, fungal, and viral infections
- Hepatitis B
- Progressive multifocal leukoencephalopathy
- Herpes zoster
- Nonmelanoma skin cancer
ARUP Lab Tests
Detect the presence of a BCR-ABL1 fusion gene to diagnose or exclude CML
Monitor for minimal residual disease (MRD)
Reverse Transcription Polymerase Chain Reaction
Assess for somatic variants in genes associated with myeloid malignancies that are relevant for diagnosis, prognosis, or clinical management in patients with MPN, MDS/MPN, and related disorders
Massively Parallel Sequencing
In addition to the above, evaluate for important genomic abnormalities in MPN that may have diagnostic, prognostic, and/or therapeutic significance, such as loss/gain of DNA or loss of heterozygosity (LOH)
Massively Parallel Sequencing/Genomic Microarray (Oligo-SNP Array)
Evaluate for mutations when diagnosis of ET or PMF is suspected
Polymerase Chain Reaction/Capillary Electrophoresis/Capillary Electrophoresis
Evaluate for the JAK2 V617F mutation in peripheral blood or bone marrow
Quantitate JAK2 V617F allele frequency to aid in risk stratification and therapeutic monitoring
Evaluate for mutations when diagnosis of PV is suspected
Polymerase Chain Reaction
Evaluate for PV in cases of high suspicion but negative JAK2 V617F mutation status
Determine diagnosis and prognosis of MPN in patients with JAK2-negative mutation
Polymerase Chain Reaction/Capillary Electrophoresis
Evaluate for ET or PMF when suspected in individuals who are negative for JAK2 V617F and CALR mutations
Polymerase Chain Reaction/Capillary Electrophoresis
Diagnose and monitor MPN and determine prognosis
Diagnose and monitor MPN and determine prognosis when bone marrow cannot be obtained
Limited role in the workup of MPNs in the setting of an otherwise optimal cytogenetic study
Fluorescence in situ Hybridization (FISH)
Use to order individual or multiple oncology FISH probes if standard FISH panels are not desired
Use to assess fibrosis in the bone marrow
Trichrome stain is used for collagen fibrosis
Initial screen for evaluation of polycythemia
Test Fact Sheet(s)
NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 3.2019. Fort Washington, PA: National Comprehensive Cancer Network. [Accessed: Oct 2019]Online
Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.Book
Reilly JT. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia. 2008; 22 (10): 1818-27.PubMed
Kanagal-Shamanna R, Hodge JC, Tucker T, et al. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genet. 2018;228-229:197-217.
Merzianu M, Groman A, Hutson A, et al. Trends in bone marrow sampling and core biopsy specimen adequacy in the United States and Canada: a multicenter study. Am J Clin Pathol. 2018;150(5):393-405.
Pomicter AD, Eiring AM, Senina AV, et al. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol. 2015;43(7):537-545.e11.
Shen W, Paxton CN, Szankasi P, et al. Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing. J Clin Pathol. 2018;71(4):372-378.
Tashi T, Swierczek S, Kim SJ, et al. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia. 2018;32(8):1830-1833.
Wang SA, Tam W, Tsai AG, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016;29(8):854-864.
Xu X, Bryke C, Sukhanova M, et al. Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genet. 2018;228-229:218-235.